RANKL Inhibition: Clinical Data

The following chapter gives an overview of the clinical data of RANKL-inhibition by denosumab in conditions of bone loss in postmenopausal osteoporosis (PO), rheumatoid arthritis (RA), and malignant bone disease (MBD).